Cargando…

Establishment of a novel lysosomal signature for the diagnosis of gastric cancer with in-vitro and in-situ validation

BACKGROUND: Gastric cancer (GC) represents a malignancy with a multi-factorial combination of genetic, environmental, and microbial factors. Targeting lysosomes presents significant potential in the treatment of numerous diseases, while lysosome-related genetic markers for early GC detection have no...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qi, Liu, Ying, Li, Zhangzuo, Tang, Yidan, Long, Weiguo, Xin, Huaiyu, Huang, Xufeng, Zhou, Shujing, Wang, Longbin, Liang, Bochuan, Li, Zhengrui, Xu, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196375/
https://www.ncbi.nlm.nih.gov/pubmed/37215115
http://dx.doi.org/10.3389/fimmu.2023.1182277
_version_ 1785044338900729856
author Wang, Qi
Liu, Ying
Li, Zhangzuo
Tang, Yidan
Long, Weiguo
Xin, Huaiyu
Huang, Xufeng
Zhou, Shujing
Wang, Longbin
Liang, Bochuan
Li, Zhengrui
Xu, Min
author_facet Wang, Qi
Liu, Ying
Li, Zhangzuo
Tang, Yidan
Long, Weiguo
Xin, Huaiyu
Huang, Xufeng
Zhou, Shujing
Wang, Longbin
Liang, Bochuan
Li, Zhengrui
Xu, Min
author_sort Wang, Qi
collection PubMed
description BACKGROUND: Gastric cancer (GC) represents a malignancy with a multi-factorial combination of genetic, environmental, and microbial factors. Targeting lysosomes presents significant potential in the treatment of numerous diseases, while lysosome-related genetic markers for early GC detection have not yet been established, despite implementing this process by assembling artificial intelligence algorithms would greatly break through its value in translational medicine, particularly for immunotherapy. METHODS: To this end, this study, by utilizing the transcriptomic as well as single cell data and integrating 20 mainstream machine-learning (ML) algorithms. We optimized an AI-based predictor for GC diagnosis. Then, the reliability of the model was initially confirmed by the results of enrichment analyses currently in use. And the immunological implications of the genes comprising the predictor was explored and response of GC patients were evaluated to immunotherapy and chemotherapy. Further, we performed systematic laboratory work to evaluate the build-up of the central genes, both at the expression stage and at the functional aspect, by which we could also demonstrate the reliability of the model to guide cancer immunotherapy. RESULTS: Eight lysosomal-related genes were selected for predictive model construction based on the inclusion of RMSE as a reference standard and RF algorithm for ranking, namely ADRB2, KCNE2, MYO7A, IFI30, LAMP3, TPP1, HPS4, and NEU4. Taking into account accuracy, precision, recall, and F1 measurements, a preliminary determination of our study was carried out by means of applying the extra tree and random forest algorithms, incorporating the ROC-AUC value as a consideration, the Extra Tree model seems to be the optimal option with the AUC value of 0.92. The superiority of diagnostic signature is also reflected in the analysis of immune features. CONCLUSION: In summary, this study is the first to integrate around 20 mainstream ML algorithms to construct an AI-based diagnostic predictor for gastric cancer based on lysosomal-related genes. This model will facilitate the accurate prediction of early gastric cancer incidence and the subsequent risk assessment or precise individualized immunotherapy, thus improving the survival prognosis of GC patients.
format Online
Article
Text
id pubmed-10196375
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101963752023-05-20 Establishment of a novel lysosomal signature for the diagnosis of gastric cancer with in-vitro and in-situ validation Wang, Qi Liu, Ying Li, Zhangzuo Tang, Yidan Long, Weiguo Xin, Huaiyu Huang, Xufeng Zhou, Shujing Wang, Longbin Liang, Bochuan Li, Zhengrui Xu, Min Front Immunol Immunology BACKGROUND: Gastric cancer (GC) represents a malignancy with a multi-factorial combination of genetic, environmental, and microbial factors. Targeting lysosomes presents significant potential in the treatment of numerous diseases, while lysosome-related genetic markers for early GC detection have not yet been established, despite implementing this process by assembling artificial intelligence algorithms would greatly break through its value in translational medicine, particularly for immunotherapy. METHODS: To this end, this study, by utilizing the transcriptomic as well as single cell data and integrating 20 mainstream machine-learning (ML) algorithms. We optimized an AI-based predictor for GC diagnosis. Then, the reliability of the model was initially confirmed by the results of enrichment analyses currently in use. And the immunological implications of the genes comprising the predictor was explored and response of GC patients were evaluated to immunotherapy and chemotherapy. Further, we performed systematic laboratory work to evaluate the build-up of the central genes, both at the expression stage and at the functional aspect, by which we could also demonstrate the reliability of the model to guide cancer immunotherapy. RESULTS: Eight lysosomal-related genes were selected for predictive model construction based on the inclusion of RMSE as a reference standard and RF algorithm for ranking, namely ADRB2, KCNE2, MYO7A, IFI30, LAMP3, TPP1, HPS4, and NEU4. Taking into account accuracy, precision, recall, and F1 measurements, a preliminary determination of our study was carried out by means of applying the extra tree and random forest algorithms, incorporating the ROC-AUC value as a consideration, the Extra Tree model seems to be the optimal option with the AUC value of 0.92. The superiority of diagnostic signature is also reflected in the analysis of immune features. CONCLUSION: In summary, this study is the first to integrate around 20 mainstream ML algorithms to construct an AI-based diagnostic predictor for gastric cancer based on lysosomal-related genes. This model will facilitate the accurate prediction of early gastric cancer incidence and the subsequent risk assessment or precise individualized immunotherapy, thus improving the survival prognosis of GC patients. Frontiers Media S.A. 2023-05-05 /pmc/articles/PMC10196375/ /pubmed/37215115 http://dx.doi.org/10.3389/fimmu.2023.1182277 Text en Copyright © 2023 Wang, Liu, Li, Tang, Long, Xin, Huang, Zhou, Wang, Liang, Li and Xu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Wang, Qi
Liu, Ying
Li, Zhangzuo
Tang, Yidan
Long, Weiguo
Xin, Huaiyu
Huang, Xufeng
Zhou, Shujing
Wang, Longbin
Liang, Bochuan
Li, Zhengrui
Xu, Min
Establishment of a novel lysosomal signature for the diagnosis of gastric cancer with in-vitro and in-situ validation
title Establishment of a novel lysosomal signature for the diagnosis of gastric cancer with in-vitro and in-situ validation
title_full Establishment of a novel lysosomal signature for the diagnosis of gastric cancer with in-vitro and in-situ validation
title_fullStr Establishment of a novel lysosomal signature for the diagnosis of gastric cancer with in-vitro and in-situ validation
title_full_unstemmed Establishment of a novel lysosomal signature for the diagnosis of gastric cancer with in-vitro and in-situ validation
title_short Establishment of a novel lysosomal signature for the diagnosis of gastric cancer with in-vitro and in-situ validation
title_sort establishment of a novel lysosomal signature for the diagnosis of gastric cancer with in-vitro and in-situ validation
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196375/
https://www.ncbi.nlm.nih.gov/pubmed/37215115
http://dx.doi.org/10.3389/fimmu.2023.1182277
work_keys_str_mv AT wangqi establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation
AT liuying establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation
AT lizhangzuo establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation
AT tangyidan establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation
AT longweiguo establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation
AT xinhuaiyu establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation
AT huangxufeng establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation
AT zhoushujing establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation
AT wanglongbin establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation
AT liangbochuan establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation
AT lizhengrui establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation
AT xumin establishmentofanovellysosomalsignatureforthediagnosisofgastriccancerwithinvitroandinsituvalidation